Pediatric patients routinely receive antiemetics to prevent acute chemotherapy-induced vomiting (CIV) on the days they receive chemotherapy. Effective tactics to prevent CIV in the days immediately following chemotherapy (delayed CIV) are more uncertain. Thus, delayed CIV may be difficult to prevent. Further, since most patients are at home when delayed CIV occurs, it may be even more difficult to detect and treat. Factors that place pediatric patients at risk of experiencing delayed/persistent CIV will be discussed. Considerations for the assessment and treatment of patients who are experiencing delayed CIV will be presented.
Lee Dupuis, RPh, ACPR, FCSHP, PhD,
Associate Scientist, Research Institute and Health Clinician Scientist, Department of Pharmacy,
The Hospital for Sick Children
Leslie Dan Faculty of Pharmacy,
University of Toronto
Lee Dupuis completed BSc, BScPhm and MScPhm degrees at the University of Toronto, a pharmacy residency at Sunnybrook Health Sciences Centre and a PhD at the University of Amsterdam. She is Associate Scientist, Research Institute, Health Clinician Scientist, Department of Pharmacy, and Clinical Pharmacist, Haematology/Oncology/Blood and Marrow Transplant Program at SickKids; and Associate Professor at the Leslie Dan Faculty of Pharmacy, University of Toronto. The focus of Lee’s research is the improvement of the supportive care of children who are receiving cancer treatment or undergoing hematopoietic stem cell transplant. She has led many studies and trials seeking to optimize supportive care by facilitating the communication of symptom severity by children, evaluating interventions to control treatment-related symptoms including the use of therapeutic drug monitoring and implementing clinical practice guidelines. She has a particular interest in improving the control of chemotherapy-induced nausea and vomiting in pediatric patients.